Date: 2015-11-03
Type of information: Development agreement
Compound: Clevegen®
Company: Faron Pharmaceuticals (Finland) Selexis (Switzerland)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: development production manufacturing
Action mechanism: monoclonal antibody. Clevegen® is an antibody designed to prevent tumour growth and metastasis which targets the tumour immune suppressor molecule, Clever-1. Clever-1 is an adhesion, scavenging and signaling molecule involved in cancer growth and is found in lymphatic and vascular endothelium as well as type 2 immunosuppressive macrophages. When Clever-1 is blocked, tumour-associated macrophages (TAM) cannot enter the tumour site and their function in the tumour as an immune suppressive cell is diminished. Both these events change the tumour environment from immune suppression to immune stimulation, allowing the host immune system to fight the tumour cells.
Disease:
Details: * On November 3, 2015, Faron Pharmaceuticals announced it has entered into an agreement with Swiss-based Selexis SA. Under the agreement, Faron will have access to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen®, its novel cancer immunotherapy antibody. Under the agreement Selexis will establish the production clones for Clevegen® for an ongoing service fee, and will also be entitled to certain milestone payments if Clevegen reaches defined clinical development stages and significant commercial sales.
Financial terms:
Latest news:
